ProKidney Q2 FY26 net loss widens to $46.44 million; revenue falls to $150,000
Reuters2026/08/10 20:10- ProKidney posted Q2 2026 revenue of $150,000, down 32.13% from a year earlier.
- Net loss before noncontrolling interest widened to $46.4 million from $37 million a year earlier.
- R&D expense climbed 39.39% to $36.1 million, driven by higher clinical study and related manufacturing costs tied to PROACT 1.
- Cash, cash equivalents and marketable securities fell to $181.6 million at June 30 from $224.9 million at March 31, supporting operations into mid-2027.
- Completed enrollment for the PROACT 1 accelerated approval analysis, with pivotal eGFR slope topline results anticipated in Q2 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CADU retransmits S1-S2 sustainability report after CNBV comments
PAMT director and 10% owner Matthew T. Moroun disposes of 3,268,000 shares worth $31.22 million
"I am now the market maker, if you want to bet against me, go ahead" Besant warns the market not to short the yen against him
Bessent stated, "When we intervene in the yen, I know exactly what the Japanese, the Bank of Japan, and Japanese policymakers are going to do." With fundamental support from the Bank of Japan's expected 25 basis point rate hike this month, short-sellers will face the dual pressure of policy intervention and an interest rate shift. Analysts believe that Bessent's tough rhetoric serves both as psychological pressure and as an indication that further actions are being prepared.
Crypto prices
More
